Refractory and unexplained chronic cough
Conditions
Interventions
None listed
Sponsors
MSD K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who have daily cough lasting more than 8 weeks. 2) Patients who have visited a doctor for chronic cough. 3)Patients who have received clinical evaluations for their chronic cough on the underlying diseases stated in Japanese guidelines such as asthma/cough variant asthma, atopic cough/laryngeal allergy, gastroesophageal reflux disease (GERD), postinfectious cough, and sinobronchial syndrome (SBS). 4) Patients who are refractory to the treatment for possible underlying diseases and continue to cough or who have chronic cough of unexplained origin even after the investigation. 5) Patients who provide written informed consent and are willing to participate in either of a 120-min focus group or a 60-min individual interview about experiences about chronic cough. 6) Patients who are 20 years and older.
Exclusion criteria
Exclusion criteria: 1)Patients who is immunocompromised. 2) Patients who has been diagnosed with chronic cough resulting from invasive respiratory tract instrumentation (e.g., ventilator dependent, endotracheal intubation, tracheostomy) or due to smoking. 3) Patients who has a comorbid respiratory condition or other illness that could exacerbate symptoms of chronic cough or that, in the opinion of the investigator, would confound interview results. 4) Patients who has a recent history of substance abuse (within the past 1 year) 5) Patients who has a diagnosis of a psychiatric disorder (e.g., schizophrenia, bipolar affective disorder) that, in the opinion of the investigator, would confound interview results. 6) Patients who has been exposed to an individual experiencing symptoms related to COVID-19 (e.g., fever, cough, shortness of breath) or has tested positive for the coronavirus.* 7) Patients who has participated in a study with any investigational medicinal product in the previous 30 days. 8) Those who have difficulties in communication via online interview tools. 9) Those who have fever (to avoid patients with acute infection)
Countries
Japan
Contacts
Public ContactTakeshi Akiyama
IQVIA Solutions Japan K.K. Real World Evidence Solutions & HEOR
Outcome results
None listed